Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;102(2):457-459.
doi: 10.1007/s00277-022-05049-6. Epub 2022 Nov 28.

Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura

Affiliations

Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura

Benson Meek et al. Ann Hematol. 2023 Feb.
No abstract available

Keywords: Anticoagulation; Caplacizumab; Hematology; Thrombotic thrombocytopenic purpura.

PubMed Disclaimer

References

    1. Hollifield AL, Arnall JR, Moore DC (2020) Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Am J Health Syst Pharm 77(15):1201–1207 - DOI
    1. Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2486–2495. https://doi.org/10.1111/jth.15006 - DOI
    1. Elverdi T et al (2021) Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert Rev Clin Pharmacol 14:1183–1188 - DOI
    1. Peyvandi F et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522. https://doi.org/10.1056/JENMoa1505533 - DOI
    1. Scully M et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335–346. https://doi.org/10.1056/NEJMoa1806311 - DOI

MeSH terms